MRK

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended June 30, 2004. The company is a research-based pharmaceutical firm facing significant financial strain due to a confluence of negative events, including the loss of marketing exclusivity for its leading product (CLARITIN), intense competition in the hepatitis C market, and substantial costs related to FDA consent decrees and legal settlements. The company operates three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health.

Key Financial Metrics

Note: Operating cash flow for Q2 is not explicitly broken out in the summary table but is included in the six-month figure. Total debt is the sum of short-term borrowings ($1,305M) and long-term debt ($2,410M) as of June 30, 2004.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 7% in Q2 2004 and 6% for the six-month period compared to 2003. This was driven by a 12% volume decline, primarily due to the switch of CLARITIN to over-the-counter (OTC) status and generic competition in the hepatitis C franchise (PEG-INTRON/REBETOL).
• Profitability Reversal: The company reported a net loss of $65 million in Q2 2004, a sharp contrast to the $182 million net income in Q2 2003. The six-month loss was $138 million versus $355 million income in the prior year.
• Special Charges: Q2 2004 included $42 million in special charges (employee termination costs). The six-month period included $112 million in special charges ($86M termination, $26M asset impairment).
• R&D Spike: R&D expenses increased 22% in Q2 to $451 million, largely due to an $80 million upfront fee for the license of garenoxacin from Toyama Chemical Co., Ltd.
• Joint Venture Income: Equity income from the cholesterol joint venture with Merck increased significantly to $77 million in Q2 (from $26 million in 2003) and $154 million for the six months (from a $4 million loss in 2003), driven by ZETIA and VYTORIN sales.

Guidance, Outlook, and Risks

Management Commentary and Outlook

Management states that the current business model is not sustainable without a dramatic change in the financial situation. The company anticipates seeking access to capital markets in 2004 to fund operations, dividends, and legal settlements. Future profitability is heavily dependent on the successful launch of VYTORIN (ezetimibe/simvastatin) and the ability to control expenses. Management cannot assure that operations will generate profits in the near term if VYTORIN is not a commercial success.

Material Risks and Contingencies

• Legal Settlements: A settlement with the U.S. Attorney's Office for the Eastern District of Pennsylvania was announced in July 2004 for $345.5 million ($291.9 million net). $177.5 million is due in 2004. Additionally, an IRS dispute regarding interest rate swaps from 1990-1992 could result in a payment of approximately $475 million ($195M tax + $280M interest) in Q3 2004.
• Consent Decree: The company is under an FDA consent decree regarding manufacturing practices. Failure to meet deadlines could result in daily fines and potential production halts. The decree is not expected to be lifted before May 2007.
• Credit Ratings: Credit ratings have been downgraded by S&P and Moody's (to Baa1 by Moody's in July 2004), resulting in higher interest rates on long-term debt and potential restrictions on commercial paper availability.
• Liquidity Mismatch: While consolidated cash exceeds debt, most cash is held by foreign subsidiaries while debt is held by the U.S. parent. Repatriating funds to the U.S. could trigger significant income taxes unless offset by U.S. operating losses.

Investor Verification Checklist

• VYTORIN Launch Performance: Verify sales traction and market share for VYTORIN following its FDA approval in July 2004, as this is the primary growth driver.
• Cash Flow Sustainability: Confirm the company's ability to fund the $177.5M Pennsylvania settlement and the potential $475M IRS payment without further dilution or distress.
• CLARITIN and Hepatitis C Decline: Monitor the rate of sales erosion in the CLARITIN (OTC) and PEG-INTRON/REBETOL franchises to assess if the bottom has been reached.
• Interest Rate Impact: Track the impact of credit rating downgrades on the cost of debt, specifically the increase in interest rates on the 2013 and 2033 notes effective December 2004.
• Consent Decree Compliance: Review progress on FDA cGMP Work Plans and revalidation programs to assess the risk of additional fines or production stoppages.